Abstract:Background We have earlier demonstrated that genetic knock out of sphingosine kinase1 (SphK1) ameliorated hyperoxia (75%) induced lung injury in a neonatal murine model of bronchopulmonary dysplasia (BPD). SphK 1 catalyzes the formation of sphingosine‐1‐phosphate (S1P), which acts through G protein coupled receptors S1P1–5. Exposure of neonatal mice pups to hyperoxia enhanced SphK1 expression and S1P levels and promoted formation of reactive oxygen species (ROS) in lungs. In vitro, exposure of human lung microvascular endothelial cells (HLMVECs) to hyperoxia (3–24 h) stimulated SphK1 activity, S1P generation and ROS production via p47 phox , which was blocked by PF‐543, a potent and specific SphK1 inhibitor. Hypothesis PF‐543 protects neonatal lungs from hyperoxia‐induced BPD. Methods Neonatal mice were administered PF‐543 (5 mg/kg/dose, intraperitoneal injection) starting on postnatal day 3 (PN3) and exposed to normoxia or hyperoxia (75% O 2 ) for 7 days. Mice received three additional doses of PF‐543, which were administered on alternate days and mice were sacrificed on PN 11. Broncho alveolar lavage (BAL) fluid and lung tissue were collected, and markers of inflammation and lung histology were evaluated. Plasma S1P levels were measured to determine the efficacy of PF‐543 in inhibiting SphK1. Results SphK1 inhibition by PF‐543 resulted in amelioration of hyperoxia‐induced BPD as evidenced by improved alveolarization characterized by decreased mean linear intercept compared to controls. Also, neonatal pups that received PF‐543 showed decreased infiltration of inflammatory cells in alveolar space, lower levels of protein and ROS in BAL fluid compared to controls. Administration of PF543 was accompanied by reduced plasma S1P levels. Conclusions Inhibition of SphK1 activity by, PF‐543 significantly reduced hyperoxia‐induced lung inflammation and BPD in newborn mice. These results suggest that PF‐543 can serve as a potential therapeutic drug to treat BPD. Support or Funding Information This work was supported by the University of Illinois at Chicago (UIC) Proof of Concept grant to A.H and by the National Institutes of Health Grant P01 HL98050 to V.N.

Electrolytes in vaginal fluid during the menstrual cycle of coitally active and inactive women.

Astragalus polysaccharides mediated preventive effects on bronchopulmonary dysplasia in rats

Anti-placental Growth Factor Antibody Ameliorates Hyperoxia-Mediated Impairment of Lung Development in Neonatal Rats

Ghrelin Ameliorates Hypoxia-Induced Pulmonary Hypertension Via Phospho-Gsk3 Β/β-Catenin Signaling in Neonatal Rats.

Ghrelin Ameliorates Hypoxia-Induced Pulmonary Hypertension Via Phospho-Gsk3 Beta/Beta-Catenin Signaling In Neonatal Rats

Astragaloside Iv Improves Bleomycin-Induced Pulmonary Fibrosis in Rats by Attenuating Extracellular Matrix Deposition

Altered Frequency of NK Cells and Treg Cells by Astragalus Polysaccharide Combined with Budesonide in Asthma Model Mice

Eclipta prostrata improves alveolar development of bronchopulmonary dysplasia via suppressing the NLRP3 inflammasome in a DLD-dependent manner

Human breast milk‐derived exosomes through inhibiting AT II cell apoptosis to prevent bronchopulmonary dysplasia in rat lung

Astragalus polysaccharides attenuate pulmonary fibrosis by inhibiting the epithelial-mesenchymal transition and NF-κB pathway activation

Recombinant CXCL17 Treatment Alleviates Hyperoxia-Induced Lung Apoptosis and Inflammation In Vivo and Vitro by Activating the AKT Pathway: A Possible Therapeutic Approach for Bronchopulmonary Dysplasia

Amino acid composition and N-terminal sequence of purified cystine binding protein of Escherichia coli.

Nesfatin‐1 alleviates hyperoxia‐induced bronchopulmonary dysplasia (BPD) via the nuclear factor‐κB (NF‐κB) p65 signaling pathway

Bone morphogenetic protein 9 protects against neonatal hyperoxia-induced impairment of lung development, inflammation and fibrosis

[Epidemiology of AIDS in Japan].

Deficiency of endothelial FGFR1 alleviates hyperoxia-induced bronchopulmonary dysplasia in neonatal mice

TGF-α/EGFR signaling promotes lipopolysaccharide-induced abnormal elastin deposition and alveolar simplification

Effect of Red Sage Root on Bronchopulmonary Dysplasis Induced by Hyperoxia in Newborn Rat

Tat-P combined with GAPR1 releases Beclin1 to promote autophagy and improve Bronchopulmonary dysplasia model

Sphingosine Kinase‐1 inhibitor, PF‐543 ameliorates Bronchopulmonary Dysplasia in a neonatal murine model

Lactobacillus plantarum L168 improves hyperoxia-induced pulmonary inflammation and hypoalveolarization in a rat model of bronchopulmonary dysplasia